Granules India is currently trading at Rs. 137.75, up by 1.30 points or 0.95% from its previous closing of Rs. 136.45 on the BSE.
The scrip opened at Rs. 137.70 and has touched a high and low of Rs. 139.75 and Rs. 137.40 respectively. So far 38826 shares were traded on the counter.
The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 157.00 on 18-May-2017 and a 52 week low of Rs. 91.45 on 09-Nov-2016.
Last one week high and low of the scrip stood at Rs. 153.50 and Rs. 132.40 respectively. The current market cap of the company is Rs. 3153.81 crore.
The promoters holding in the company stood at 53.45%, while Institutions and Non-Institutions held 11.54% and 35.01% respectively.
Granules India is reportedly planning to invest $35 million to expand operations of its wholly owned subsidiary Granules Pharmaceuticals Inc in the US. The pharmaceutical research & development and manufacturing capacities of the subsidiary will get a boost with the funding.
Currently, it is a 100,000-sq foot facility in the Chantilly area of Fairfax County, Virginia. The company conducts research and development to formulate products, and intends to manufacture products in the location as well.
Granules India, the Hyderabad-head quartered company, manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates and finished dosages. It intends to increase its global presence with a firm base and operations in the US.
